<DOC>
	<DOC>NCT01738841</DOC>
	<brief_summary>This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra™) used in routine practice in children aged 12 months to 12 years living in the Philippines.</brief_summary>
	<brief_title>Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines</brief_title>
	<detailed_description>The participating physicians will enroll only those subjects for whom they would prescribe Priorix-Tetra in the course of their normal clinical practice.</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol. Written informed consent obtained from the parent(s)/LAR(s) of the subject. Male or female subjects living in the Philippines between, and including, the ages of 12 months and 12 years at the time of the vaccination. Female subjects of child bearing potential may be enrolled in the study, if the subject: has agreed to be abstinent or practiced adequate contraception for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 3 months after completion of the vaccination. Child in care. Any contraindications to vaccination as stated in the Prescribing Information. Acute, severe febrile illness at the time of enrollment. The presence of a minor infection, such as a cold, will not exclude the subject from the study. Previous receipt of a measles, mumps, rubella and/or varicellavirus containing vaccine less than 3 months prior to study entry. Previous enrolment in this trial. Subjects with impaired immune function, including primary or secondary immunodeficiencies based on medical history. History of hypersensitivity to any component of the vaccine. History of hypersensitivity following previous administration of measles, mumps, rubella and/or varicellavirus containing vaccines. Receipt of human gamma globulins or a blood transfusion within 3 months prior to study entry. Hypersensitivity to latex. Pregnant or lactating female.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Combined measles-mumps-rubella-varicella vaccine</keyword>
	<keyword>Priorix-Tetra™</keyword>
	<keyword>MMRV</keyword>
	<keyword>children</keyword>
	<keyword>Post-marketing surveillance</keyword>
	<keyword>Philippines</keyword>
</DOC>